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Abstract 
 
Objective 
Blindness is a recognised complication of giant cell arteritis (GCA); however the frequency and 
risk factors for this complication have not been firmly established. This study examined the 
incidence and determinants of blindness in patients with GCA using a large international 
cohort. 
Methods 
The analysis was conducted among subjects recruited into the Diagnosis and Classification 
Criteria in Vasculitis Study (DCAVS). The study captures consecutive patients presenting to 
clinic-based physicians. New onset blindness was assessed six months after diagnosis by 
completion of the Vasculitis Damage Index (VDI). Logistic regression analysis was used to 
assess the association between blindness and clinical variables. 
Results 
Of 433 patients with GCA from 26 countries, 7.9% presented with blindness in at least one 
eye at six months. Risk factors identified at baseline for blindness at six months were 
identified and included prevalent stroke (OR = 4.47, 95% CI: 1.30 to 15.41), and peripheral 
vascular disease (OR = 10.44, 95% CI: 2.94 to 37.03). 
Conclusion 
This is the largest study to date of subjects with incident GCA and confirms that blindness 
remains a common complication of disease and is associated with established vascular 
disease.  
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Trial registration: American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic 
Vasculitis (DCVAS), https://clinicaltrials.gov/ct2/show/NCT01066208, ClinicalTrials.gov 
Identifier: NCT01066208.
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Introduction 
Giant cell arteritis (GCA) is the commonest form of large vessel vasculitis, with an estimated 
annual incidence of up to 32.8 per 100,000 individuals > 50 years old (1). Blindness is a well-
recognised complication of GCA; however, information to date on the occurrence of visual 
loss in GCA is inconsistent and difficult to interpret. Previous studies have been conducted in 
small, selected, hospital-based patient series using different definitions of disease and clinical 
outcome resulting in imprecise estimates of risk, ranging from 2.9% to 66.2% (2, 3). Registry-
based surveys have involved larger sample sizes but include less precise clinical detail. 
Prompt treatment of patients with GCA with glucocorticoids may prevent visual loss but rarely 
reverses established changes (4) and better understanding is needed of the factors which 
place subjects at particular risk at the time they first present. Studies have implicated pre-
existing vascular disease as a potential risk factor for subsequent visual loss in GCA (5-9). 
However considerable uncertainty remains as no single vascular risk factor has been reported 
consistently. 
In this analysis we examine the rate of visual loss in the Diagnostic and Classification Criteria 
in Vasculitis Study (DCVAS), a large international cohort of well characterised patients with 
GCA (10).  We examine the potential risk factors for blindness and focus on the association of 
vascular disease with ophthalmologic outcomes in GCA. 
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Patients and Methods 
Setting 
DCVAS was set-up in 2010 and recruits patients from 129 sites worldwide. The purpose of 
DCVAS is to develop and validate diagnostic and classification criteria for systemic vasculitis 
for use in daily clinical practice and in clinical trials. Physicians recruit patients with diagnoses 
of vasculitis or comparator conditions at the time of diagnosis. Information collected includes 
clinical, serological, pathological and radiological data.  
Case Ascertainment - GCA Definition 
As part of the DCVAS protocol, the examining physician was required to submit an assessment 
of their level of diagnostic certainty (very certain, ≥75%; moderately certain, 50-74%; 
uncertain, 25-49%; very uncertain, <25%) for each participant. Musculoskeletal features were 
also recorded but not whether patients had a prior diagnosis of polymyalgia rheumatica. 
Patients were included in the present analysis if they had a new baseline diagnosis of GCA 
(i.e. not relapsing disease) which was confirmed after six months with a confidence level of 
≥75%. Also available were the results of temporal artery biopsy (TAB) to allow patients to be 
classified using the 1990 ACR criteria set for GCA (11). A positive TAB was defined as the 
presence of inflammatory cell infiltrate and / or presence of giant cells. 
Definition of Blindness 
The occurrence of new onset blindness at six months was assessed using the Vasculitis 
Damage Index (VDI) (12) which defines blindness in one or both eyes as complete loss of 
vision. Also recorded at baseline were data on ophthalmic features (amaurosis fugax – 
transient monocular blindness, sudden ongoing visual loss – loss of vision either visual field 
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defect or blindness, blurred vision, or diplopia – double vision). VDI also records diplopia and 
visual impairment as a single item. This was not included as a primary outcome measures due 
to the lack of consistency in definition. 
Previous medical history 
The DCVAS protocol records for all patient the previous history of medical conditions present 
before the onset of the current illness. Conditions specifically documented include: coronary 
heart disease, heart failure, peripheral vascular disease, hypertension requiring medication, 
chronic obstructive pulmonary disease, asthma, diabetes mellitus, cerebrovascular accident, 
dyslipidaemia and malignancy. These diagnoses were defined as, in common with many large 
registry datasets, a physician recorded entry in the patients’ care record. 
Statistical Approach 
Descriptive statistics were used to assess patient characteristics, with standard 
nonparametric tests used to assess differences between groups. Previous publications have 
found an association between laboratory markers and subsequent blindness including 
relatively lower inflammatory markers, anaemia and thrombocytosis (5, 6, 13). For these 
reasons inflammatory markers: Erythrocyte Sedimentation Rate (ESR, C - reactive protein 
(CRP), and haematological tests: anaemia – haemoglobin (Hb) <100 g/L and platelets > 500 x 
10⁹/L were assessed for their association with subsequent blindness  
Previous data suggested a relationship between prior vascular disease and ischaemic 
complications in GCA. A logistic regression analysis was applied to examine the strength of 
the association between vascular risk factors with blindness at six months recorded as odds 
rations (OR) with 95% confidence intervals (CI). In a sensitivity analysis, the models were 
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recalculated firstly using the 1990 ACR criteria set and secondly positive temporal artery 
biopsy findings to define GCA diagnosis. 
Statistical analysis was carried out using STATA version 12 (StataCorp LP, Texas). 
  
8 
 
Results 
Of the 715 patients recruited into DCVAS by December 30, 2014 with complete data, 433 
were considered to have GCA with ≥75% diagnostic certainty at six months; 404 fulfilled the 
1990 ACR criteria for GCA; and 235 had a positive TAB. The patients were in the main (95.6%) 
Caucasians from Europe or North America (baseline characteristics - Table 1). Six months after 
diagnosis, 34 (7.9%) patients had monocular blindness, of whom 3 (0.7%) had binocular 
blindness (no statistical significant difference in the rate of blindness between men and 
women). 
Thirty-one of the patients that had blindness recorded at six months (22 women and 12 men) 
had presented with symptoms of sudden visual loss, with only two patients without visual 
disturbance (including amaurosis fugax, visual loss, blurred vision or diplopia) at baseline 
being declared blind at six months. The visual manifestations of disease for all patients with 
GCA at presentation included: blurred vision in 98 (22.6%), sudden visual loss in 70 (16.2%), 
diplopia in 51 (11.8%), amaurosis fugax in 33 (7.6%), and red eyes in nine (2.1%). As expected, 
blindness at six months occurred more frequently in those who presented with visual 
symptoms. Of those with sudden visual loss at presentation, 44.3% (31/70) were blind at six 
months as assessed on the VDI; of those with no recorded visual loss at presentation, 0.8% 
(3/363) were recorded as being blind at the six month review. Patients who developed 
blindness had a lower CRP at presentation; however, no other clinical feature of GCA itself 
was associated significantly with blindness at 6 months. 
Table 2 shows the results of logistic regression analysis examining associations between 
potential vascular risk factors assessed at baseline and blindness (adjusted for age and sex). 
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Factors positively associated with blindness at six months included i) a prior history of 
cerebrovascular accident (CVA) (OR = 4.47, 95% CI: 1.30 to 15.41), and ii) peripheral vascular 
disease (PVD) (OR = 10.44, CI: 2.94 to 37.03). There was no association between baseline 
laboratory findings and blindness. 
In the sensitivity analysis the findings were largely unchanged. The rates of blindness in those 
meeting the 1990 ACR criteria and those with a positive TAB were 7.4% and 9.8%, 
respectively. The associations between PVD and CVA remained statistically significant with 
positive associations for blindness at six months (for PVD, ACR cases OR = 9.40, (2.14 to 41.34), 
TAB positive cases OR = 9.22, (1.56 to 54.70), for CVA, ACR cases OR = 5.29, (95% CI 1.39 to 20.07), 
TAB positive cases OR = 4.02, (0.89 to 18.16)). The association between prevalent diabetes 
mellitus and blindness reached statistical significance for those cases defined by positive TAB 
(4.28, CI: 1.42 to 12.92) but not the cases defined by 1990 ACR criteria (2.24, CI: 0.84 to 5.96). 
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Discussion 
This large observational study demonstrates that blindness remains a major problem in GCA. 
Around one in twelve patients is blind in one eye by six months after diagnosis. Most patients 
who develop blindness do so by the time of their first assessment with only two patients 
without symptoms of visual disturbance suffering blindness at six months. These results re-
emphasise the need for urgent referral and rapid institution of glucocorticoid therapy (14). 
Our analysis shows an association between blindness and peripheral vascular disease. 
The rate of blindness identified in the present study is lower than the majority of published 
estimates, possibly reflecting our narrower and more stringent definition of blindness. It could 
be that more patients suffered visual loss since 70 patients were noted to have this 
complication at their baseline visit. However, data from the Mayo clinic published data on 
204 cases of GCA from Rochester, Minnesota, USA over a 55-year period revealed patients 47 
(23.0%) had visual symptoms, with seven (3.4%) suffering blindness in one eye (of whom two 
had bilateral blindness), which is lower than our estimate (15). Subsequently this same 
research group reported that 8.2% of patients with GCA had permanent visual loss attributed 
to their vasculitis; these newer data are more consistent with our current estimate (16). Our 
estimate is higher than the 2.9% reported in the register-based study conducted by Mollan et 
al.(2), interpretation of which is limited both by the fact that the cases were identified though 
hospital episodes, and that classification criteria were not applied, potentially leading to an 
underestimate of the rate of blindness in those with GCA. In addition care episodes, rather 
than individual patient records were used leading to the potential for double or multiple 
counting. 
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In keeping with other studies, a lower mean inflammatory marker result was noted in those 
with blindness, which reached statistical significance for CRP but not for ESR. It may be that 
patients with lower inflammatory markers at baseline assessment are at greater risk of 
blindness due to prior inadequate treatment with glucocorticoids, equally it may be a factor 
that contributes to diagnostic delay, or reflect a propensity for inflammation in smaller 
vessels. We also identified prior peripheral vascular disease as a risk factor for blindness in 
patients with GCA. Previous studies have implicated hypertension, a past history of ischaemic 
heart disease, thrombocytosis, constitutional symptoms, and low inflammatory response as 
potential risks for blindness (5, 6, 17). While reports have been inconsistent and many of these 
factors were not confirmed in the present study, taken together these findings suggest a 
potential role of endothelial dysfunction in both the development of GCA and its ischaemic 
complications. The increased risk of CVD following a diagnosis of GCA is also consistent with 
this hypothesis (18). 
A strength of this study is its size: 433 new cases of GCA were included, each of which had a 
systematic structured assessment that included presenting features, comorbidities, and 
outcome at six months. Outcomes were assessed by the VDI, a validated means of recording 
permanent damage arising from vasculitis or its treatment. 
Limitations of the study include referral bias due to the fact that it was clinic, rather than 
population-based. However, our sample was not selected from an individual specialty or 
specialist centre, providing potentially greater generalisability than prior single-centre 
studies. A formal ophthalmological assessment was not carried out routinely as part of DCVAS 
and the study protocol does not include additional review of the care records. Other 
limitations include the descriptions used for visual change and loss within the DCVAS case 
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report form, which we were concerned may not have been uniformly applied. We therefore 
chose to use the most definitive outcome measure available, i.e., complete loss of vision in 
the affected eye.  
It is difficult to comment in full on the detailed causal pathways involved in those whose 
symptoms evolved over the six months of follow-up, but we note that only two patients 
without any visual disturbance were declared blind in one eye at six months. Our analysis of 
obesity and blindness needs to be treated with caution due to the relatively high proportion 
of missing values for BMI in this dataset. We do not have information regarding the initial 
dose or route or timing of glucocorticoid therapy or anti-platelets such as aspirin. We do note 
however, that recent database studies in GCA (18, 19) have not included glucocorticoid 
treatment as a separate covariate, because their use is advised as the standard management 
for GCA (20), and it was therefore not considered possible to separate the effect of treatment 
and disease. This is the largest study to date of visual loss in cases of clinically-confirmed GCA 
and provides a robust estimate of blindness associated with a diagnoses of GCA. Blindness, 
both monocular and binocular, remains a major problem in GCA and this study points to the 
need to be especially vigilant of this outcome in patients with a higher conventional vascular 
risk. 
Key Messages 
 Data from 26 countries reveals 7.9% of patients with GCA are blind within six months. 
 Prior history of peripheral vascular disease and stroke is associated with greatest risk 
of blindness. 
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Table 1. Clinical Features at baseline of patients with giant cell arteritis 
Clinical Features Physician Diagnosis of GCA at 6 months 
(>75% certainty) n=433  
  
Blind at six months 
(n=34) 
Not blind at six 
months (n=399) p value* 
Age at diagnosis (median, years) 74.9 73.0 0.073 
Male (%) 12 (35.3) 133 (33.3) 0.816 
New-onset headache 23 (67.7) 282 (70.7) 0.710 
Any visual symptom (%) 32 (94.1) 154 (38.6) 0.000 
Jaw claudication (%) 13 (38.2) 163 (40.9) 0.766 
Tongue claudication (%) 3 (8.8) 16 (4.0) 0.188 
Morning stiffness shoulders arms 
(%) 
7 (20.6) 87 (21.8) 0.869 
Morning stiffness hips/thighs (%) 5 (14.7) 69 (17.3) 0.700 
Myalgia (%) 5 (14.7) 109 (27.3) 0.109 
Fever (%) 3 (8.8) 68 (17.0) 0.214 
Fatigue (%) 13 (38.2) 164 (41.1) 0.744 
Weight loss (%) 12 (35.3) 138 (34.6) 0.934 
Smoking Status 
   
Current (%) 4 (14.0) 56 (11.8) 0.741 
0.741 
0.741 
Former (%) 9(31.1) 124 (26.5) 
Never (%) 21 (54.9) 219 (61.8) 
Comorbidities 
   
Coronary heart disease (%) 2 (5.9) 27 (6.8) 0.843 
Heart failure (%) 0 (0.0) 9 (2.26) 0.376 
Peripheral vascular disease (%) 5 (14.7) 6 (1.5) 0.000 
Hypertension requiring therapy (%) 15 (44.1) 164 (41.1) 0.732 
Diabetes mellitus (%) 7 (20.6) 33 (8.3) 0.017 
Cerebrovascular accident (%) 4 (11.8) 10 (2.5) 0.003 
Dyslipidaemia (%) 10 (29.4) 87 (21.8) 0.307 
Chronic obstructive Pulmonary 
disease 
0 (0.0) 24 (6.0) 0.141 
Laboratory test results at 
presentation (%) 
   
Positive temporal artery biopsy 23 (67.7) 203 (50.9) 0.060 
Median ESR mm/hr 65 70 0.620 
Median CRP mg/L 46 64 0.025 
Anaemia (Haemoglobin <100g/L) 
(%) 
4 (11.8) 62 (15.5) 0.803 
Thrombocytosis (platelets > 500 x 
10⁹/L) (%) 
3 (8.8) 
 
75 (18.8) 0.330 
*p-value of difference between those who were subsequently declared blind in at least one eye 
versus those who were not; all calculated using the chi squared test except for median age at 
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diagnosis, ESR and CRP which was tested by the Mann-Whitney test. GCA: giant cell arteritis; ESR: 
erythrocyte sedimentation rate; CRP: C - reactive protein.
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Table 2. Association between vascular disease factors assessed at presentation and blindness at 6 months. 
Presenting features Physician Diagnosis of GCA at 6 months 
(>75% certainty) n=433 
1990 ACR Criteria cases 
n=404 
TAB positive cases 
n=235 
  Unadjusted OR, 95% CI Adjusted* OR, 95% CI Adjusted* OR, 95% CI Adjusted* OR, 95% CI 
BMI† 1.10, (1.01 to 1.19) 1.10, (1.02 to 1.20) 1.10, (1.00 to 1.21) 1.13, (1.00 to 1.28) 
Smoking (ever vs never) 0.75, (0.37 to 1.55) 0.78, (0.36 to 1.68) 0.65, (0.28 to 1.54) 0.70, (0.26 to 1.84) 
Cardiovascular disease at baseline 0.86, (0.20 to 3.79) 0.77, (0.17 to 3.45) 0.77, (0.16 to 3.58) 2.02, (0.38 to 10.78) 
Diabetes at baseline 2.88, (1.16 to 7.10) 2.48, (0.98 to 6.25) 2.26, (0.82 to 6.17) 4.19, (1.39 to 12.67) 
Stroke at baseline 5.19, (1.54 to 17.53) 4.47, (1.30 to 15.41) 5.29, (1.39 to 20.07) 4.02, (0.89 to 18.16) 
Peripheral vascular disease at 
baseline 11.29, (3.25 to 39.23) 10.44, (2.94 to 37.03) 9.40, (2.14 to 41.34) 9.22, (1.56 to 54.70) 
Hyperlipidaemia at baseline 1.49, (0.69 to 3.24) 1.45, (0.67 to 3.15) 1.43, (0.62 to 3.29) 2.20, (0.87 to 5.60) 
Hypertension on medication at 
baseline 1.13, (0.56 to 2.29) 0.99, (0.48 to 2.03) 1.11, (0.51 to 2.39) 0.73, (0.30 to 1.79) 
*Adjusted for age and sex. †Missing data for BMI (n = 131).  
GCA: giant cell arteritis; OR: odds ration; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C -reactive protein. 
 
 
